Floatz logo

Lopinavir

HIV Infectious Disease

International Maternal Pediatric Adolescent AIDS Clinical Trials GroupSmall moleculePhase 4 / ApprovedDormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
81/ 100

Competitive context

59 Active assets in the HIV Infectious Disease cohort.

Asset / SponsorPhaseRating
Raltegravir
Helsinki University Central Hospital
Phase 4A
Efavirenz
The Cleveland Clinic
Phase 4BBB
Retrovir
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BBB
Nevirapine Anhydrous
Germans Trias i Pujol Hospital
Phase 4BBB
Abacavir
Germans Trias i Pujol Hospital
Phase 4BBB

View all 46 →

Same molecule, other indications

Lopinavir is also rated in:

lipodystrophyDormant
BB
Indicative · Phase 4
69 / 100
View asset →
nutritional deficiency diseaseDormant
B
Indicative · Phase 4
63 / 100
View asset →
hepatitis C virus infectionDormant
B
Indicative · Phase 3
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →